Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review

  • ID: 4395079
  • SWOT Analysis
  • 45 pages
  • GlobalData
1 of 5
Therapist Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Therapist Biosciences Ltd (Therapist), formerly NASA Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabis based pharmaceuticals for the treatment of central nervous system disorders. Therapies major product candidates include THX-110, for the treatment of Tourette syndrome, obstructive sleep apnea and chronic pain; THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-150, for the treatment of infectious diseases; and THX-160, for the treatment of treat pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapist Biosciences is headquartered in Tel Aviv, Israel.

Therapist Biosciences Ltd Key Recent Developments

Jul 12, 2018: Cure acquires Therapies cannabis non-pain pipeline
Jul 11, 2018: Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapist Biosciences
May 31, 2018: Therapist Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
May 15, 2018: Therapist Biosciences Issues CEO's Letter to Shareholders
May 09, 2018: Dual-Listed Therapist to Voluntarily Delist from Tel Aviv Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Section 1 - About the Company
Therapix Biosciences Ltd - Key Facts
Therapix Biosciences Ltd - Key Employees
Therapix Biosciences Ltd - Key Employee Biographies
Therapix Biosciences Ltd - Major Products and Services
Therapix Biosciences Ltd - History
Therapix Biosciences Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
Therapix Biosciences Ltd - Business Description
Therapix Biosciences Ltd - Corporate Strategy
Therapix Biosciences Ltd - SWOT Analysis
SWOT Analysis - Overview
Therapix Biosciences Ltd - Strengths
Therapix Biosciences Ltd - Weaknesses
Therapix Biosciences Ltd - Opportunities
Therapix Biosciences Ltd - Threats
Therapix Biosciences Ltd - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Therapix Biosciences Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments
Jul 12, 2018: Cure acquires Therapix’s cannabinoid-based non-pain pipeline
May 31, 2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
May 15, 2018: Therapix Biosciences Issues CEO's Letter to Shareholders
May 09, 2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange
Jan 09, 2018: Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update at the Biotech Showcase 2018
Jan 09, 2018: Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update at the Biotech Showcase 2018
Nov 10, 2017: Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids
Nov 09, 2017: Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update
Nov 07, 2017: Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders
Nov 02, 2017: Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer

Section 6 – Appendix
Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables
Therapix Biosciences Ltd, Key Facts
Therapix Biosciences Ltd, Key Employees
Therapix Biosciences Ltd, Key Employee Biographies
Therapix Biosciences Ltd, Major Products and Services
Therapix Biosciences Ltd, History
Therapix Biosciences Ltd, Subsidiaries
Therapix Biosciences Ltd, Key Competitors
Therapix Biosciences Ltd, Ratios based on current share price
Therapix Biosciences Ltd, Annual Ratios
Therapix Biosciences Ltd, Interim Ratios
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Therapix Biosciences Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Therapix Biosciences Ltd, Performance Chart (2013 - 2017)
Therapix Biosciences Ltd, Ratio Charts
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Rimonyx Pharmaceuticals Ltd
  • Compugen Ltd
  • BiondVax Pharmaceuticals Ltd
  • Bio-Cell Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll